Antibody and EGFR–STAT1 pathway point to new fibrosis treatments
Researchers at Yale found a human antibody that blocks epiregulin and lowers fibrosis markers. They also show EGFR activates STAT1 in fibroblasts, suggesting two treatment paths: block epiregulin or target the EGFR–STAT1 pathway.